We focus on therapies for the treatment of bronchopulmonary disease
This section of the website provides information for existing and potential investors in Vectura Group plc including financial reports, an interactive share price chart and updates on our latest news.
Vectura's focused application of technology, know-how and expertise has demonstrated that the potential for new inhaled pharmaceuticals with real therapeutic and commercial value can be realised.
Vectura Group plc interim results for the six months ending 30 September 2014
Annual Report and Accounts for Year Ended 31 March 2014
JP Morgan Healthcare Conference, London
18 Nov 2014
Vectura Group plc - Interim Results for the six months ended 30 September 2014
19 Aug 2014
Vectura Group plc - Interim Management Statement
19 Nov 2014
Czech and Irish Approval for AirFluSal Forspiro
18 Nov 2014
Appoints Andrew Oakley as Group CFO
Share price table
Berenberg European Conference, Surrey
Stay informed Register to our news alert and receive latest updates on news and events
For general enquiries, call us on +44 (0)1249 667700. For more specific enquiries, visit Contact us
Most computers will open PDF documents automatically, but you may need to download Adobe Reader.